ABIVAX Société Anonyme (EPA:ABVX)
France · Delayed Price · Currency is EUR | Market Cap | 9.35B +106.0% |
| Revenue (ttm) | 4.92M -59.8% |
| Net Income | -332.20M |
| EPS | -4.52 |
| Shares Out | 86.20M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,218 |
| Open | 111.30 |
| Previous Close | 108.50 |
| Day's Range | 110.00 - 112.30 |
| 52-Week Range | 57.50 - 139.00 |
| Beta | -0.21 |
| Analysts | Buy |
| Price Target | 138.56 (+24.16%) |
| Earnings Date | Sep 21, 2026 |
About ABIVAX Société Anonyme
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn’s disease. The company was incorporated in 2013 and is headquartered in Paris, France. [Read more]
Financial Performance
In 2025, ABIVAX Société Anonyme's revenue was 4.57 million, a decrease of -63.22% compared to the previous year's 12.43 million. Losses were -336.10 million, 90.7% more than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for ABVX stock is "Buy." The 12-month stock price target is €138.56, which is an increase of 24.16% from the latest price.
News
Abivax $920 million cash haul lets it prepare for solo U.S. launch instead of relying on a buyer, CEO tells CNBC
Abivax's latest funding round allows the biotech to move toward a U.S. launch of its bowel disease drug without backing from Big Pharma, its CEO told CNBC on Friday. The French biotech has been under ...
ABIVAX Société Anonyme Slides: Corporate presentation
ABIVAX Société Anonyme has posted slides in relation to its latest quarterly earnings report, which was published on July 10, 2026.
Abivax Announces Closing of $920 Million Public Offering
Abivax Announces Closing of $920 Million Public Offering PARIS, France, July 6, 2026 –10:05 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a cl...
Abivax Shares Continue Climbing After Biotech Firm Moves to Bolster Balance Sheet
Shares rose 5% after the biotech moved to bolster its balance sheet through an upsized stock offering, signaling investor appetite in the wake of positive clinical-trial data.
Abivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M)
Abivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M)
Abivax nears $11 billion valuation after fundraising eases M&A pressure
Abivax SA raised $800 million in an expanded share sale on Wednesday after strong investor demand, valuing the French biotechnology company at nearly $11 billion and easing pressure to pursue a near...
Correction: Abivax Announces Pricing of Highly Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares
Abivax Announces Pricing of Highly Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares
Abivax announces trading resumption of its ordinary shares on Euronext Paris
Abivax announces trading resumption of its ordinary shares on Euronext Paris PARIS, France, July 1, 2026 – 02:50 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”)...
Abivax Announces Pricing of Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares
Abivax Announces Pricing of Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris PARIS, France, July 1, 2026 – 07:30 a.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Compa...
Abivax Announces Launch of Public Offering of American Depositary Shares
Abivax Announces Launch of Public Offering of American Depositary Shares PARIS, France – June 30, 2026 – 10:45 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or t...
French biotech stock soars 25% after new data on experimental medicine
The late-stage clinical trial data of the medicine, released late on Monday, showed that malignancies were in line with expected background rates. In this article ABVX
Abivax inflammatory bowel drug shows benefit in relapsed and non-responding patients
Abivax said on Monday its experimental ulcerative colitis drug helped harder-to-treat groups of patients achieve remission, with the biotech calling the results a boost to the safety profile of its ...
ABIVAX Société Anonyme Transcript: Study result
ABTECT Maintenance Part 2 results show obefazimod delivers robust, durable efficacy and a favorable long-term safety profile in highly refractory ulcerative colitis patients. Exposure-adjusted safety events remain within expected ranges, supporting regulatory confidence and broad clinical use.
ABIVAX Société Anonyme Press release: Study result
ABIVAX Société Anonyme issued a press release on June 29, 2026, disclosing material business information to investors.
ABIVAX Société Anonyme Slides: Study result
ABIVAX Société Anonyme has posted slides in relation to its latest quarterly earnings report, which was published on June 29, 2026.
Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory Ulcerative Colitis Patients and Strengthening the Phase 3 Maintenance Safety Database
Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory Ulcerative Colitis Patients and Strengthening the Phase 3 Maintenance...
Abivax Investigation Initiated: SueWallSt Investigates the Officers and Directors of Abivax (ABVX)
Jefferies downgraded Abivax from Buy to Hold and slashed its price target by nearly 44% after rare cancer cases emerged in the company's Phase 3 ulcerative colitis trial -- shares more than 40% of the...
Abivax Shares Plunge After Company Reports Adverse Events in Key Drug Trial
The biotech said some patients developed cancer in a late-stage clinical trial for the bowel-disease drug that were unrelated to the treatment.
Abivax stock crashes as safety fears overshadow bowel disease drug trial win
Abivax shares fell 31% even after the French biotech reported strong late-stage data for obefazimod, its experimental treatment for ulcerative colitis. The once-daily oral therapy met the main goal an...
Abivax shares sink after key trial results for inflammatory bowel drug
Abivax shares tumbled on Tuesday after the French biotech reported late-stage data for its experimental inflammatory bowel drug, with investors focusing on safety concerns even as the treatment showe...
Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update
Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update
Abivax's inflammatory bowel drug meets main goal of late stage trial
Abivax said on Monday its experimental drug for patients with ulcerative colitis, a type of chronic inflammatory disease, met the main goal of a closely watched late-stage trial.
ABIVAX Société Anonyme Transcript: Study result
The phase III ABTECT maintenance trial in ulcerative colitis showed both 25 mg and 50 mg obefazimod achieved best-in-class clinical and endoscopic remission rates with a favorable safety profile over 44 weeks, outperforming current therapies and supporting dose flexibility for future use.
ABIVAX Société Anonyme Press release: Study result
ABIVAX Société Anonyme issued a press release on June 1, 2026, disclosing material business information to investors.